These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 26485258)
1. Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. Teo BH; Lansdell P; Smith V; Blaze M; Nolder D; Beshir KB; Chiodini PL; Cao J; Färnert A; Sutherland CJ PLoS Negl Trop Dis; 2015; 9(10):e0004068. PubMed ID: 26485258 [TBL] [Abstract][Full Text] [Related]
2. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Happi CT; Gbotosho GO; Folarin OA; Milner D; Sarr O; Sowunmi A; Kyle DE; Milhous WK; Wirth DF; Oduola AM Malar J; 2006 Oct; 5():82. PubMed ID: 17020611 [TBL] [Abstract][Full Text] [Related]
3. Atovaquone and proguanil hydrochloride: a review of nonclinical studies. Pudney M; Gutteridge W; Zeman A; Dickins M; Woolley JL J Travel Med; 1999 May; 6 Suppl 1():S8-12. PubMed ID: 23573546 [TBL] [Abstract][Full Text] [Related]
4. In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand. Khositnithikul R; Tan-Ariya P; Mungthin M Malar J; 2008 Jan; 7():23. PubMed ID: 18226262 [TBL] [Abstract][Full Text] [Related]
5. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Sutherland CJ; Laundy M; Price N; Burke M; Fivelman QL; Pasvol G; Klein JL; Chiodini PL Malar J; 2008 Nov; 7():240. PubMed ID: 19021900 [TBL] [Abstract][Full Text] [Related]
6. Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options. Meltzer E; Rahav G; Schwartz E Clin Infect Dis; 2018 May; 66(11):1751-1755. PubMed ID: 29228132 [TBL] [Abstract][Full Text] [Related]
7. Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. Pimentel S; Nogueira F; Benchimol C; Quinhentos V; Bom J; Varandas L; do Rosário V; Bernardino L Malar J; 2006 Apr; 5():30. PubMed ID: 16597338 [TBL] [Abstract][Full Text] [Related]
8. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Musset L; Bouchaud O; Matheron S; Massias L; Le Bras J Microbes Infect; 2006 Sep; 8(11):2599-604. PubMed ID: 16962361 [TBL] [Abstract][Full Text] [Related]
9. Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. Staines HM; Burrow R; Teo BH; Chis Ster I; Kremsner PG; Krishna S J Antimicrob Chemother; 2018 Mar; 73(3):581-595. PubMed ID: 29237012 [TBL] [Abstract][Full Text] [Related]
10. Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo. Massamba L; Madamet M; Benoit N; Chevalier A; Fonta I; Mondain V; Jeandel PY; Amalvict R; Delaunay P; Mosnier J; Marty P; Pomares C; Pradines B Malar J; 2020 Jan; 19(1):37. PubMed ID: 31964401 [TBL] [Abstract][Full Text] [Related]
11. Failure of atovaquone-proguanil chemoprophylaxis and chloroquine treatment in Plasmodium malariae infection. Visser R; de Mast Q; Munnix I; van der Ven A; Dofferhoff T Travel Med Infect Dis; 2016; 14(6):644-645. PubMed ID: 27546283 [No Abstract] [Full Text] [Related]
13. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. McKeage K; Scott L Drugs; 2003; 63(6):597-623. PubMed ID: 12656656 [TBL] [Abstract][Full Text] [Related]